33 results about "Intoxicative inhalant" patented technology

Method for electrostatically depositing select doses of medicament powder at select locations on a substrate. Specifically, the apparatus contains a charged particle emitter for generating charged particles that charge a predefined region of a substrate and a charge accumulation control circuit for computing the amount of charge accumulated upon the substrate and deactivating the emitter when a selected quantity of charge has accumulated. Additionally, a triboelectric charging apparatus charges the medicament powder and forms a charged medicament cloud proximate the charged region of the substrate. The medicament particles within the medicament cloud electrostatically adhere to the charged region. The quantity of charge accumulated on the substrate at the predefined region and the charge-to-mass ratio of the medicament powder in the cloud control the amount (dose) of medicament deposited and retained by the substrate. Consequently, this apparatus accurately controls both medicament dosage and deposition location. Furthermore, since the substrate can be of any dielectric material that retains an electrostatic charge, the apparatus can be used to deposit medicament on substrates that are presently used in oral medicament consumption, e.g., substrates that are used to fabricate suppositories, inhalants, tablets, capsules and the like.

A method of countering terrorism or hostile activity in an airplane by using a built-in defense system within the aircraft. The defense system includes chemical sprays, laser guns, and pre-programmed sound alarm systems. The aerosol chemicals range from benign fogging agents to non-lethal incapacitating agents from the categories of inhalants, general anesthetics, and irritants. Any of the systems can be used singly or in any combination. These systems can be activated manually from the control panel in the cockpit, or via a remote wireless system by the flight crew from anywhere within the plane. Such activation being password and code protected.

Stabilized bacteriophage compositions, and methods for preparing stabilized bacteriophage compositions are provided. The method for producing an antibacterial composition involves adsorbing an aqueous solution of one or more bacteriophages, or one or more phage components, onto a matrix to produce a composition, and drying the composition to produce the antibacterial composition. An antibacterial composition comprising one or more strain of bacteriophage, or one or more phage component, adsorbed onto a matrix is also provided. The antibacterial composition may also be encapsulated. The antibacterial composition, or the encapsulated antibacterial composition, may be used within a cream, lotion or gel, be admixed with a pharmaceutical carrier and administered topically, orally, nasally, used as a powdered inhalant, or the antibacterial composition or encapsulated antibacterial composition, may be added to a feed for animal, aquatic or avian uses.

The invention discloses inhalant, a preparation method thereof, and application of the inhalant as an inhalant carrier with pullulan. The particle diameter of drug particles for lung inhalation in the dry-powder inhalant disclosed by the invention is 0.1-50 mu m, preferably 0.3-15 mu m, more preferably 0.5-5 mu m. Generally, the dosage of drugs inhaled for each time is 0.1 mu g to 500 mg. The effective deposition rate of the inhalant in the lung is increased by 16-400%. The inhalant has high bioavailability and can be used for treating local or systemic diseases. The inhalant disclosed by the invention has important value for increasing the pulmonary delivery efficiency of drugs.

A system includes but is not limited to at least one manifold; an inhalant dissemination device coupled to the at least one manifold; an inhalant characterization device coupled to the at least one manifold; and a control module operably coupled to the inhalant dissemination device and the inhalant characterization device, said control module configured to (a) determine an inhalant concentration in a manifold, and (b) calculate at least one of a retrospective and a prospective inhaled dose in response to the inhalant concentration, and (c) start and stop a flow through the manifold until the at least one of the retrospective and the prospective inhaled dose is greater than or equal to a specified dose. A method includes but is not limited to starting a flow of an inhalant through a manifold; determining an inhalant concentration of the inhalant in the manifold; and stopping the flow of the inhalant through the manifold when the inhalant concentration is in a first specified inhalant-concentration range.

An inhalant exposure unit and system that provides controlled flow of inhalant to an animal with a breathing system that provide controlled exposure of inhalant, minimized breathing of exhaled air and control of exhaust flow.

The present invention relates to a method of increasing the carbon dioxide level in a patient in by administering to the patient an inhalant that comprises a mixture of carbon dioxide and atmospheric air. The method can be used to treat a patient suffering from asthma, allergies, muscle tension, pain, insomnia, and/or mental stress. The present invention also relates to a device that may be used in a method of an inhalant that comprises a mixture of carbon dioxide and atmospheric air to a patient.

The invention relates to application of radish chitin conjugated protein in preparing oral hygiene products such as toothpaste, dental floss, mouth wash, oral spray or inhalant, and chewing gum and so on The oral hygiene products are used for removing and/or reducing dental plagues and/or bacteria in the oral cavity, thereby reducing the incidence of odontopathies (decayed tooth, periodontal disease, etc.) and halitosis.

The invention belongs to the technical field of medicine, and relates to a fudosteine inhalant and a preparation method thereof. The fudosteine inhalant provided by the invention is prepared from 60 to 90 percent of fudosteine and 10 to 40 percent of lactose, wherein the percentage is the mass percentage; the particle diameter D90 of the fudosteine is preferably 2 mu m to 5 mu m. The invention provides a fudosteine dry powder inhalant with high bioavailability.

The present invention provides a kind of preparation for treating allergic rhinitis and asthma, and features that each ml of the preparation contains isoforskolin 0.005-0.4 mg except medicine supplementary material and is prepared into acceptable inhalant. The preparation has high stability, no irritation to skin including damaged skin and relatively high antiphlogistic effect. It has curative effect on allergic rhinitis and bronchial asthma, and is practical.

The invention discloses an effective portion of traditional Chinese medicament for resisting influenza virus, which is prepared from selfheal 5-200 parts, mulberry leaf 5-1-00 parts, wild chrysanthemum flower 5-100 parts as raw material through disintegrating, and supercritical CO2 extraction. The effective portion can be prepared into tablets, capsules, granules, oral liquids, injections, inhalants, sprays or drop pills.

The invention belongs to the field of biotechnology pharmaceutical preparations, and relates to a dry powder inhaler of an interferon. The dry powder inhaler, having single dose of 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 40 mg or 60 mg, contains 1-100 [mu]g of interferon and an appropriate amount of a pharmaceutically acceptable adjuvant for the dry powder inhaler; the interferon is composed of an interferon alpha and an interferon lambda in a weight ratio of (1:19)-(19:1). The dry powder inhaler of interferon provided by the invention is used for treating viral pneumonia and can significantly improve the therapeutic effect in comparison with the dry powder inhaler of the interferon alpha or the dry powder inhaler of the interferon lambda used alone.

The invention relates to a peramivir solution type inhalant and a preparation method thereof. The solution type inhalant is prepared from peramivir, an osmotic pressure adjusting agent, a pH adjustingagent and water, the concentration of the peramivir is more than 15 mg/ml, the concentration of the osmotic pressure adjusting agent is less than 8 mg/ml, the pH of the solution type inhalant is 5.0-6.0, heating sterilizing is not adopted, and the osmotic pressure adjusting agent is selected from chlorine, sodium or glucose. The solution type inhalant has better stability and excellent lung targeting, which significantly improves the effectiveness and safety of medicines.

The present invention relates to a substitute smoking agent for cigarette. Its raw material composition includes 0.3-1.5mg of nicotine, 0.3-2g of fluorotrichloromethane, 0.1-0.8g of aerosol made up by mixing dry ice and ice according to the ratio of 1:2-5, 0.005-0.05g of tobacco flavouring agent and 0-0.5g of nutrients necessary for human body. Said invention also provides its preparation method and concrete steps.

The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.

The invention relates to an externally applied compound composition consisting of tadines and a leukotriene antagonist, wherein the tadines are preferably loratadine and salt thereof; and the leukotriene antagonist is preferably montelukast and salt thereof. The externally applied compound composition can be prepared into externally applied preparations such as nasal drops, eye drops, eye ointments, ointments, gel, inhalants, patches and the like. The externally applied compound composition can be used for local treatment for allergic diseases, can quickly improve allergic symptoms, and has the characteristics of high efficiency, safety, convenient use and the like.

The invention discloses application of cannabinoids in the preparation of inhalants. Inhaling the inhalants takes short time which is shorter than 1 min for a patient; the inhalants act fast; peakingtime of blood concentration is short; the inhalants are highly bioavailable.

The invention belongs to the technical field of traditional Chinese medicine, and discloses medicine for treating rhinitis and a preparation method thereof. The medicine for treating rhinitis is prepared from the following raw materials in parts by mass: 5 to 15 parts of Chinese honeylocust fruits, 10 to 40 parts of muskmelon pedicel, 10 to 20 parts of radix angelicae, 5 to 15 parts of rhizoma chuanxiong, 3 to 5 parts of herba asari, 10 to 20 parts of lonicera japonica, 10 to 30 parts of herba ephedrae, 10 to 30 parts of flos magnoliae, 10 to 30 parts of fructus xanthii and 5 to 20 parts of rhizoma acori tatarinowii. An inhalant can directly reach the affected part to sufficiently achieve the maximum effects of the medicine; the discomfort is instantly relieved, so that a patient feels that uncomfortable symptoms of stuffy and running noise and the like are relieved; the use is convenient; the time limitation is avoided. The medicine invented by combining the ancient external use medicine spraying method with the modern medicine pharmacological research; the clinic effects are obvious. The clinic evaluation is performed according to the following curative effect standards: ineffectiveness: symptoms of stuffy noise, itching nose, paroxysmal sneezing and runny nose and are like are not changed; effectiveness: the symptoms are relieved; excellent effectiveness: the symptoms are obviously relieved.

The invention discloses a Chinese ephedra and semen armeniacae amarae lung-freeing traditional Chinese medicine composition and a preparation method thereof, and the Chinese ephedra and semen armeniacae amarae lung-freeing traditional Chinese medicine composition comprises the following raw materials in parts by weight: 2-8 parts of Chinese ephedra, 2-8 parts of mint, 2-8 parts of periostracum cicadae, 2-18 parts of honeysuckle, 4-18 parts of radix scutellariae, 4-16 parts of semen armeniacae amarae, 2-9 parts of thunberg fritillary bulb, 2-8 parts of platycodon grandiflorum, 2-8 parts of liquorice, 2-8 parts of jasmine, 10-20 parts of radix aucklandiae and 80-170 parts of refined honey. A Chinese ephedra and semen armeniacae amarae lung-freeing granule or drink disclosed by the inventionhas the effects of tonifying qi and tonifying deficiency, freeing lung, moistening dryness, reducing phlegm and relieving cough, relieving pain and resolving masses, and has the function of enhancingthe immunity of the organism, the traditional Chinese medicine composition is beneficial to emission of harmful inhalants, has the effects of freeing lung and moistening dryness, relieving cough and relieving sore throat, has a good effect on symptoms such as cough and excessive phlegm, and can be prepared into honeyed pills, can be taken with warm water and is convenient to use; the problem thatin the prior art the Chinese ephedra and semen armeniacae amarae lung-freeing traditional Chinese medicine composition is particles and needed to be taken by mixing with boiled water is solved.

The invention relates to a transdermal patch capable of relieving nasal obstruction and aims to effectively solve the problems that U-shaped inhalants cause discomfort in use and externally-applied patches are short in acting time, excessively low in adhesion and easy to fall off. The technical scheme adopted by the invention is as follows: the transdermal patch capable of relieving nasal obstruction is composed of an anti-adhesion layer 1, an adhesion layer 2 and a backing layer 3, wherein the adhesion layer 2 is an externally-applied product prepared by taking menthol, eucalyptus oil and ethanol as raw materials, taking an acrylate adhesive as a substrate, mixing, coating and die cutting; the adhesion layer is prepared from the following raw materials in percentage by weight: 4-6% of eucalyptus oil, 1.5-2.5% of menthol, 70-76% of acrylate adhesive and 18-22% of ethanol. The transdermal patch is safe and non-toxic and is pleasant in fragrance, convenient to use and free of discomfort;the acrylate adhesive layer is high in viscidity, steady to stick, difficult to fall off and long in acting time, is capable of rapidly relieving the nasal obstruction symptom, and is a great innovation in nasal patch products.

A device and method of use thereof enable a portable device to be moveably disposed between a smoker and an output access point of a smoking pipe. The device temporarily forms a channel for inhalants to pass from a smoking pipe to a user's mouth. The smoking pipe may be selected from at least two different pipe structures. A cross section of the channel may be circular, orthogonal or elliptical. The device may include a particulate filter positioned between an inhalant input location and inhalant output location of the device. The filter may be insertable and removable from the tube. A source ledge may extend outward from the inhalant input location and/or a mouth end ledge may extend beyond a cross-section of the channel. A plurality of removable mouthpieces may be alternatively coupled and removed from the inhalant output location. The mouthpiece or a source piece may be elastic.